A small study has found lixisenatide, a GLP-1 made by Sanofi, may slow the progression of Parkinson’s disease, according to findings published April 3 in The New England Journal of Medicine.
A small study has found lixisenatide, a GLP-1 made by Sanofi, may slow the progression of Parkinson’s disease, according to findings published April 3 in The New England Journal of Medicine.
Copyright © 2024 | WordPress Theme by MH Themes